Atyr Pharma Inc. (NASDAQ:LIFE)’s share price was down 5.5% during trading on Thursday . The company traded as low as $2.88 and last traded at $2.93, with a volume of 267,473 shares. The stock had previously closed at $3.10.

A number of equities analysts recently commented on LIFE shares. William Blair cut Atyr Pharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 31st. Zacks Investment Research raised Atyr Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. Finally, BMO Capital Markets reaffirmed a “hold” rating on shares of Atyr Pharma in a report on Thursday, May 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $23.75.

The company’s 50 day moving average price is $2.84 and its 200-day moving average price is $3.99. The firm’s market cap is $70.35 million.

Atyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.02. Equities analysts predict that Atyr Pharma Inc. will post ($2.79) EPS for the current year.

In related news, insider Grove Matsuoka acquired 12,412 shares of the company’s stock in a transaction dated Wednesday, May 11th. The shares were purchased at an average cost of $3.04 per share, with a total value of $37,732.48. Following the completion of the acquisition, the insider now directly owns 2,412 shares of the company’s stock, valued at $7,332.48. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.